MedMatrix Rx
Daily 340B Morning Briefing
Recent developments in the 340B program show significant shifts affecting drug manufacturers and healthcare providers. Drugmakers, including AbbVie, Bristol Myers Squibb, and Boehringer Ingelheim, are seeking to intervene in a lawsuit concerning HRSA’s rebate plans. This action reflects growing tensions between pharmaceutical companies and regulatory bodies. Concurrently, HRSA has approved rebate plans from ten manufacturers for its revised 340B Rebate Model Pilot Program, set to commence in January 2027. In a contrasting move, CMS has proposed a $4.55 billion reduction in 340B drug payments, which could adversely affect hospital revenues and outpatient drug costs. An ASPE report raises concerns about the growth of the 340B program, suggesting it may contribute to higher drug costs and hospital consolidation. These developments reveal the complexities and challenges facing the 340B program as stakeholders address regulatory changes and financial pressures.
EXECUTIVE SUMMARY
01
Drugmakers seek to intervene in 340B lawsuit.
AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, and PhRMA filed motions to join the lawsuit defending HRSA’s rebate plans.
AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, and PhRMA filed motions to join the lawsuit defending HRSA’s rebate plans.
Source: Becker’s Hospital Review
02
HRSA names 10 drugmakers for 340B rebate pilot.
HRSA approved rebate plans from 10 manufacturers for the revised 340B Rebate Model Pilot Program starting January 2027.
HRSA approved rebate plans from 10 manufacturers for the revised 340B Rebate Model Pilot Program starting January 2027.
Source: Fierce Pharma
03
CMS proposes 340B payment cuts.
CMS proposed reducing 340B drug payments by $4.55 billion, impacting hospital revenues and outpatient drug costs.
CMS proposed reducing 340B drug payments by $4.55 billion, impacting hospital revenues and outpatient drug costs.
Source: TechTarget
04
Ponaman comments on HRSA and CMS data initiatives.
Ponaman Healthcare Consulting identified the operational changes required by HRSA’s rebate pilot and CMS’s data repository.
Ponaman Healthcare Consulting identified the operational changes required by HRSA’s rebate pilot and CMS’s data repository.
Source: MENAFN
05
ASPE report criticizes 340B program growth.
ASPE’s report raises concerns about 340B’s growth, suggesting it incentivizes higher drug costs and hospital consolidation.
ASPE’s report raises concerns about 340B’s growth, suggesting it incentivizes higher drug costs and hospital consolidation.
Source: STAT News
EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. The proposed cuts to 340B drug payments by CMS, amounting to $4.55 billion, pose a significant threat to covered entities, particularly hospitals that rely on these funds to support their operations and patient care initiatives. As these entities face reduced revenues, they may struggle to maintain essential services, especially for vulnerable populations that depend on affordable medications. The financial strain could lead to increased drug costs for patients and potentially limit access to critical healthcare services. Furthermore, the ongoing legal challenges and the involvement of major drug manufacturers in the lawsuit may complicate the regulatory environment, creating uncertainty for covered entities as they plan their financial and operational strategies in the coming years.
Emerging risks.
- Hospitals face financial strain from increased administrative costs under the 340B rebate model.
- The lawsuit against HRSA’s rebate pilot could delay or alter its implementation, affecting hospital budgets.
- CMS’s proposed payment cuts may reduce hospital revenues, impacting service delivery.
- The expansion of the 340B program may lead to increased scrutiny and regulatory changes.
- Drugmakers’ intervention in the lawsuit could influence court decisions and policy outcomes.
Emerging opportunities.
- Hospitals can use the delay bill to advocate for favorable 340B program reforms.
- Covered entities may optimize operations by adapting to new data submission requirements.
- The CMS repository is a chance to refine claims data accuracy and compliance.
- Engagement in policy discussions can shape future 340B program adjustments.
- Hospitals may explore alternative funding sources to offset potential revenue losses.
Key actions for providers.
- Hospitals should prepare for potential changes in 340B rebate structures and reimbursement rates.
- Engage with policymakers to influence the outcome of the 340B rebate pilot and related legislation.
- Review and update compliance processes to meet HRSA and CMS data requirements.
- Monitor legal proceedings and adjust financial strategies accordingly.
- Collaborate with industry groups to advocate for hospital interests in 340B policy debates.
TOP STORIES
HRSA names 10 drugmakers for 340B rebate pilot.
Fierce Pharma · October 2, 2026
- HRSA approved plans from 10 manufacturers for the pilot.
- The pilot starts on January 1, 2027.
- It includes a larger list of drugs than the first attempt.
- CMS launched a data repository for Part D 340B claims.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
Ponaman comments on HRSA and CMS data initiatives.
MENAFN · October 20, 2026
- Ponaman identified changes required by HRSA’s rebate pilot.
- Covered entities must submit claims data within 45 days.
- Manufacturers must respond to rebate requests within 10 days.
- CMS’s repository tests data for rebate calculation use.
LITIGATION & ENFORCEMENT WATCH
| Court | Matter | Date |
|---|---|---|
| D. Me. | AMERICAN HOSPITAL ASSOCIATION v. KENNEDY — Motion to Intervene by AbbVie Inc., pharmacyclics LLC, bristol-myers squibb company, boehringer ingelheim pharmaceuticals, inc. Responses due by 11/4/2026. Case filed October 9, 2026. [source] | October 14, 2026 |
| M.D. Fla. | Florida Health Sciences Center, Inc. v. Eli Lilly and Company — Response to Motion re motion to Dismiss Plaintiff’s Complaint and As-Applied Challenge to the Constitutionality of Section 501.201 to 501.213, Fla. Stat. Case filed July 2, 2026. [source] | October 14, 2026 |
| S.D.N.Y. | Mount Sinai Hospital v. CVS Health Corporation — Protective ORDER.regarding procedures to be followed that shall govern the handling of confidential material. (.). Case filed May 18, 2026. [source] | October 13, 2026 |
| D.N.H. | Mary Hitchcock Memorial Hospital v. Eli Lilly and Company — Surreply to Reply to 5 motion for Preliminary Injunction Def’s Surreply in Opposition to Plt’s Motion for Preliminary Injunction. Case filed July 27, 2026. [source] | October 6, 2026 |
| 8th Cir. | Astrazeneca Pharmaceuticals, LP v. Marty Jackley — Reply to response to petition for initial hearing en banc. Case filed August 11, 2026. [source] | September 25, 2026 |
| 8th Cir. | Pharm. Res. & Mfr. of America v. Marty Jackley — Motion to file a reply to response,. Case filed August 25, 2026. [source] | September 25, 2026 |
| N.D. Ill. | Novartis Pharmaceuticals Corporation v. Raoul, in his official capacity as Attorney General for the State of Illinois — Order signed by the Honorable Edmond E. Chang. For the reasons stated in the Order, the motion for expedited discovery 34 is denied. Case filed August 7, 2026. [source] | September 24, 2026 |
| E.D. Mo. | AbbVie Inc. v. Hanaway — Memorandum and order: Accordingly, the Court grants Intervenors’ motion to intervene. see order for details. Case filed July 22, 2024. [source] | September 24, 2026 |
SOCIAL MEDIA & STAKEHOLDER SENTIMENT
I conducted a web search for recent stakeholder and social commentary on the U.S. 340B Drug Pricing Program from the past 90 days, focusing on reactions, statements, op-eds, and advocacy positions from hospital and health-center groups, provider and patient advocates, drug manufacturers, PBMs, and policy commentators, including LinkedIn posts, Reddit discussions, and Substack/newsletter opinions.
High drug launch prices stress health system, report says
Axios · October 21, 2026
- Main theme: High drug launch prices are placing financial pressure on the U.S. healthcare system.
- Stakeholder sentiment: The pharmaceutical industry, represented by PhRMA, disputes the report’s methodology and asserts it overlooks broader pricing trends and competitive market dynamics.
- Potential implications: The report details the financial strain on the healthcare system due to escalating drug prices.
- Credibility: Axios is a reputable news outlet known for its in-depth reporting.
Why health care stocks are rallying
Axios · October 19, 2026
- Main theme: Health care stocks are experiencing a rally amid expectations of policy changes following the midterm elections.
- Stakeholder sentiment: Analysts suggest that Democratic control of Congress could lead to delays in scheduled cuts to Medicaid reimbursement rates, benefiting health care equities.
- Potential implications: The potential policy shift could impact health care stocks and reimbursement rates.
- Credibility: Axios is a reputable news outlet known for its in-depth reporting.
ASHP Opposes HRSA’s Revised 340B Rebate Model Pilot
ASHP News · July 31, 2026
- Main theme: ASHP opposes HRSA’s revised 340B rebate model pilot due to increased administrative burden and costs.
- Stakeholder sentiment: Tom Kraus, ASHP chief advocacy officer, stated, “Rebates in both the 340B program and the Inflation Reduction Act negotiated pricing program improperly shift costs from manufacturers to providers, effectively raising the costs of medications in direct opposition to congressional intent.”
- Potential implications: The opposition could influence the implementation of the 340B rebate model pilot.
- Credibility: ASHP is a professional association representing pharmacists and is a credible source on pharmacy-related matters.
Providers warn of another decade of 340B payment problems
TechTarget · August 31, 2026
- Main theme: Providers warn of prolonged 340B payment issues due to proposed reimbursement cuts.
- Stakeholder sentiment: The American Hospital Association cautioned that finalizing reimbursement cuts could lead to “another decades-long payment battle.”
- Potential implications: The warning suggests potential prolonged disputes over 340B reimbursement rates.
- Credibility: TechTarget is a reputable source for healthcare industry news.
WHAT TO WATCH NEXT
- Congressional action on the 340B Rebate Model Delay Act. [source]
- Implementation of HRSA’s revised 340B rebate pilot on January 1, 2027. [source]
- HRSA’s interim summaries of pilot findings by April 30, 2028. [source]
End of briefing.
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.